No Boost in Outcomes for Clear Cell RCC With Higher Belzutifan Dose

(MedPage Today) -- NASHVILLE, Tenn. -- A higher dose of belzutifan (Welireg) being investigated for advanced clear cell renal cell carcinoma (ccRCC) did not improve outcomes as compared with the usual dose in other settings, a randomized trial...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news